Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children

AIDS

Volumn 24, Issue 1, 2010, Pages 139-146

  Yotebieng, Marcel ^a,b   Van Rie, Annelies ^a   Moultrie, Harry ^b   Meyers, Tammy ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

ART monitoring; CD4; Children; South Africa; Viral load; Weight

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ARTICLE; BODY HEIGHT; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOUTH AFRICA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; SOUTH AFRICA; VIRAL LOAD; WEIGHT GAIN;

EID: 73649145505     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328332d5ca     Document Type: Article

References (33)

1. UNAIDS. 2007 AIDS epidemic update. 2007. pp. 1-50. http:// data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. Accessed (21 September 2009).
2. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243.
3. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use of anti-retroviral agents in pediatric HIV infection. 2008. pp. 1-139. http://aidsinfo.nih.gov/ContentFiles/ PediatricGuidelines.pdf. Accessed (20 September 2009).
4. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Geneva, Switzerland: World Health Organization; 2006. pp. 1-144.
5. Kober K, Van Damme W. Scaling up access to antiretroviral treatment in southern Africa: who will do the job? Lancet 2004; 364:103-107.
6. World Health Organization. Task shifting: rational redistribution of tasks among health workforce teams, global recommendations and guidelines. 2007. pp. 1-86. http://data.unaids.org/ pub/Manual/2007/ttr-taskshifting-en.pdf. Accessed (21 September 2009).
7. Meyers T, Eley B, Leoning W. Guidelines for the management of HIV-infected children. Johannesburg: Jacana Media; 2005.
8. Carey VJ, Yong FH, Frenkel LM, McKinney RM. Growth velocity assessment in paediatric AIDS: smoothing, penalized quantile regression and the definition of growth failure. Stat Med 2004; 23:509-526.
9. WHO Multicentre Growth Reference Study Group (2009). WHO child growth standards: growth velocity based on weight, length and head circumference- methods and development. Geneva, Switzerland: World Health Organization. p. 242.
10. Rigby RA, Stasinopoulos DM. Generalized additive models for location, scale and shape. J R Stat Soc Ser C Appl Stat 2005; 54:507-554.
11. Rigby RA, Stasinopoulos DM. Smooth centile curves for skew and kurtotic data modelled using the Box-Cox power exponential distribution. Stat Med 2004; 23:3053-3076.
12. Royston P, Wright EM. Goodness-of-fit statistics for age-specific reference intervals. Stat Med 2000; 19:2943-2962.
13. van Buuren S, Fredriks M. Worm plot: a simple diagnostic device for modelling growth reference curves. Stat Med 2001; 20:1259-1277.
14. Wei Y, Pere A, Koenker R, He X. Quantile regression methods for reference growth charts. Stat Med 2006; 25:1369-1382.
15. Stasinopoulos D, Rigby R. Generalized additive models for location scale and shape (GAMLSS) in R. J. Stat Software 2007; 23:1-56.
16. Stasinopoulos D, Rigby R, Akantziliotou C. Instructions on how to use the GAMLSS package in R. 2nd ed. London: STORM Centre, London Metropolitan University; 2008. Technical report 01/06.
17. Bakshi SS, Britto P, Capparelli E, Mofenson L, Fowler MG, Rasheed S, et al. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zido-vudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. J Infect Dis 1997; 175:1039-1050.
18. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 1997; 336:1704-1712.
19. Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, McKinney RE Jr, et al. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. Pediatrics 1998; 101:214-220.
20. McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, et al. A randomized study of combined zidovu-dine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 study team. J Pediatr 1998; 133:500-508.
21. Baumgartner RN, Roche AF, Himes JH. Incremental growth tables: supplementary to previously published charts. Am J Clin Nutr 1986; 43:711-722.
22. Roche AF, Himes JH. Incremental growth charts. Am J Clin Nutr 1980; 33:2041-2052.
23. Collett D (2003). Modelling survival data in medical research. 2nd ed. Florida: Chapman&Hall/CDC.
24. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. Adv, Data 2000: 314: 1-27
25. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height, and body mass index-for-age-methods and development. Geneva, Switzerland: WHO.
26. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80:557-572.
27. Benjamin DK Jr, Miller WC, Ryder RW, Weber DJ, Walter E, McKinney RE Jr. Growth patterns reflect response to antiretroviral therapy in HIV-positive infants: potential utility in resource-poor settings. AIDS Patient Care STDS 2004; 18:35-43.
28. Carey VJ, Yong FH, Frenkel LM, McKinney RE Jr. Pediatric AIDS prognosis using somatic growth velocity. AIDS 1998; 12:1361-1369.
29. Cameron N, DeWet T, Ellison G, Bogin B. Growthinheightand weight of South African urban infants from birth to five years: the Birth to Ten study. Am J Hum Biol 1998; 10:495-504.
30. Moultrie H, Yotebieng M, Kuhn L, Meyers T. Mortality and virological outcomes of 2105 HIV-infected children receiving ART in Soweto, South Africa. In: Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
31. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary healthcare facilities in Zambia. JAMA 2007; 298:1888-1899.
32. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-489.
33. Voss LD, Wilkin TJ, Bailey BJ, Betts PR. The reliability of height and height velocity in the assessment of growth (the Wessex Growth study). Arch Dis Child 1991; 66:833-837.